FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

Kenji Tamura, Chikako Shimizu, Takashi Hojo, +10

Annals of Oncology

Breast OncologyOncologyMetastatic SettingsMedicineImmunology +7

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry

Naoki Niikura, Ai Tomotaki, Hiroaki Miyata, +13

Annals of Oncology

Breast OncologyMedicinePharmacologyBreast CancerCancer Treatment +8

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

K. Aogi, Hiroji Iwata, Norikazu Masuda, +6

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicinePathologyPhase Ii Study +6

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

Masakazu Toi, Hiroji Iwata, Yasuhiro Fujiwara, +15

British Journal of Cancer

Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates.

K. Aogi, K Kitahara, I Buley, +4

PubMed

Telomerase EnzymeCell DivisionClinical SamplesTelomerase ActivityMedicine +8

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Shinji Ohno, Louis W.C. Chow, Nobuaki Sato, +19

Breast Cancer Research and Treatment

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)

Noriyuki Katsumata, Toru Watanabe, Hironobu Minami, +8

Annals of Oncology

Metastatic Breast CancerOncologyBreast OncologyMedicinePhase Iii Trial +9

Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

Masakazu Toi, SJ Lee, Shoichiro Ohtani, +14

Cancer Research

Breast OncologyAdjuvant CapecitabinePathologyDfs EventsX Arm +14

Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients

Daisuke Takabatake, Naruto Taira, Fumikata Hara, +7

Japanese Journal of Clinical Oncology

Telomerase activity in soft-tissue and bone sarcomas.

K. Aogi, A Woodman, Virginia Urquidi, +2

PubMed

OncologyTelomerase EnzymeMalignant DiseaseOncogenic AgentMedicine +9